Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

y 31, 2008, the Company had cash and cash equivalents totaling $23,263,000, compared to $11,379,000 at July 31, 2007. The increase in cash and cash equivalents is the result of a private placement completed on December 19, 2007, when the Company issued 10,040,000 common shares for gross proceeds totaling $16,867,200. The total number of common shares issued as of January 31, 2008, was 46,375,335, compared to 36,335,335 in the same period last year. At January 31, 2008, the Company's working capital was $23,016,000, compared to $11,468,000 at July 31, 2007. After taking into consideration the Company's anticipated revenue, planned research and development expenditures and the assumption that there will not be unanticipated expenses, the Company expects that its current working capital will be sufficient to finance operations beyond the 2010 fiscal year.

The Company will continue to seek additional funding, primarily by way of equity offerings, to carry out its business plan and to minimize risks to its operations. The market, however, for equity financings for companies such as Helix is challenging, and there can be no assurance that additional funding by way of equity financing will be available. The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing or delaying one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. Any additional equity financing, if secured, may result in significant dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, including technology licensing, co-development collaborations and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products. There can be no assurance, however, that any alternative sources of funding will be available.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... On Friday, December 19, 2014, President Obama ... Resolution Appropriations Act of 2015, which for the first ... through the Congressionally Directed Medical Research Programs (CDMRP) administered ... (HA), working in conjunction with its allies on Capitol ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
(Date:12/24/2014)... 2014 The report expects global cell isolation ... also provides a carefully analyzed data about the vital drivers, ... Full Copy of Report @ http://bit.ly/1yUxy0T , According ... keep witnessing growth at an impressive CAGR during near future. ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... AKRON, Ohio , June 16 On Wednesday, June 23 ... promises to inspire renewed hope for new jobs in Ohio . ... will share their insight on innovation, global commerce and the new skills needed ... www.ohio.com/jobgrowth . , , , ...
... and SAN DIEGO , June 16 ... Biosciences, Inc. (Nasdaq: NBIX ) today announced that ... and commercialize elagolix for the treatment of endometriosis-related pain. ... antagonist, which has recently completed a phase IIb study ...
... ... in a new denture retention system procedure that can add 20% profit to a dental practice. ... (PRWEB) June 16, 2010 -- The ... new denture retention system procedure that can add 20% profit to a dental practice the ...
Cached Biology Technology:Free Web Cast On Fueling Ohio's New Job Growth 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 3Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 4Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 5Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 2Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 3Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 4
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... in molecular targeting, translational cancer research and cancer ... 17,000 scientists from around the world gather at ... the 2008 Annual Meeting of the American Association ... the meeting will include late-breaking clinical trial findings ...
... plant withers unproductively or thrives in salty conditions may ... mechanism that controls salt tolerance has been found in ... collaborating with an international team. Complex-N-glycan, a ... previously thought to have no helpful function for plant ...
... A. Strobel, Professor of Molecular Biophysics and Biochemistry, ... Award. The award is given by American ... outstanding scientific contributions made by young researchers early ... award lecture, titled Three Views of RNA Catalysis: ...
Cached Biology News:AACR annual meeting showcases developments in understanding and targeting cancers 2AACR annual meeting showcases developments in understanding and targeting cancers 3Salt-tolerant gene found in simple plant nothing to sneeze at 2Yale University's Strobel recognized for work on RNA 2
Lipid Phosphate Phosphohydrolase 2...
Adhesion Molecule Antibodies...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Biology Products: